Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis

Deng, Shuwen; Wu, Lei; Hoog, G. S. de; Yang, Lu; Vitale, Roxana G.; Rafati, Hasan; Seyedmousavi, M.; Tolooe, Ali; Lee, H.A.L. van der; Liao, Wanqing; Verweij, Paul E.; Seyedmousavi, Seyedmojtaba

doi:10.1128/aac.00270-18

Cited by 12 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the synergistic effect of TBF and AMB for F. nubica zssy0803 was not accidental. These results were consistent with those of previous studies 5 , 23 , 24 . AMB is a cheap antifungal drug used to treat CBM due to Fonsecaea species before triazoles have emerged 25 - 28 .…”

Section: Discussionsupporting

confidence: 93%

Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo

Zhang

et al. 2019

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Chromoblastomycosis is a chronic fungal infection. Itraconazole and terbinaﬁne are the most recommended antifungal drugs for chromoblastomycosis, while amphotericin B is not usually recommended. A patient with chromoblastomycosis in our hospital showed poor clinical responses to itraconazole and terbinaﬁne. The fungus isolated from the lesions of this patient was identified as Fonsecaea nubica and numbered zssy0803. In vitro antifungal susceptibilities of F. nubica zssy0803 to terbinaﬁne, amphotericin B, itraconazole, voriconazole and caspofungin were evaluated, as well as the combinations of terbinaﬁne with the other four antifungals. The combined effect of terbinaﬁne and amphotericin B on other 20 clinical F. nubica strains was also evaluated. The minimal inhibitory concentrations of terbinaﬁne, amphotericin B, itraconazole, voriconazole and caspofungin on F. nubica zssy0803 were 0.25 μg/mL, 2 μg/mL, 1 μg/mL, 4 μg/mL and 8 μg/mL, respectively. The combination of terbinaﬁne and amphotericin B showed the lowest fractional inhibitory concentration index of 0.28 to F. nubica zssy0803 in comparison with combinations of terbinaﬁne and the other four antifungal drugs. The combination of terbinaﬁne and amphotericin B was also synergistic for all the other 20 F. nubica strains. Then, the combination of oral terbinaﬁne (500 mg/day) and intralesional injections of amphotericin B (1 mg/mL) was used to treat this patient. After this combined therapy for 25 weeks and terbinaﬁne monotherapy for additional 12 weeks, the patient was cured. These findings indicate for the first time that terbinaﬁne and amphotericin B are synergistic in killing F. nubica both in vitro and in vivo .

show abstract

Section: Discussionsupporting

confidence: 93%

Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo

Zhang

et al. 2019

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…In clinical practice, for instance, HIV-PIs are administered in combination with antiretroviral regimens for acquired immunodeficiency syndrome therapy 53 . Drugs toxicity in the CBM treatment and the increase of resistant strains have driven studies on a combined therapy 54,55 . The benefits of this therapy are well-known and include a broad spectrum efficacy, greater potency than monotherapy, reduction emergence of resistance as well as improvements in both safety and tolerability [56][57][58] .…”

Section: Discussionmentioning

confidence: 99%

Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

Granato

Sousa

Rosa

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

“…FECMM members are encouraged to use their FECMM title in the corresponding author contact (or the author byline) to increase the visibility of their status and this initiative. In return, publications of FECMM will be promoted via the ECMM Twitter account (ie, @ EurConfMedMycol) and the homepage …”

Section: Ecmm Academymentioning

confidence: 99%

“…In return, publications of FECMM will be promoted via the ECMM Twitter account (ie, @ EurConfMedMycol) and the homepage. 32 The audit takes place by collecting data on how laboratory diagnosis is performed and on how clinical management of IFD is effectively executed. As a basis of the laboratory audit, the best practice recommendations for the diagnosis of serious fungal diseases will be used.…”

Section: Ecmm: His Tory Miss I On and Working G Roupsmentioning

confidence: 99%

Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together

Hoenigl

Gangneux

Segal

et al. 2018

Mycoses

View full text Add to dashboard Cite

Invasive mycoses present a global challenge with expansion into new hosts, emergence of new pathogens, and development of multidrug resistance. In parallel, new antifungal agents and advanced laboratory diagnostic systems are being developed. In response to these evolving challenges, the European Confederation of Medical Mycology (ECMM) is committed to providing international expertise, guidance, and leadership with the key objectives of improving diagnosis, treatment, outcome, and survival of persons with invasive fungal diseases. Representing 25 affiliated National Medical Mycology Societies, the ECMM has developed several major ways to achieving these critical objectives: (a) tasking specific medical mycology working groups; (b) founding the ECMM Academy and Fellow program (FECMM); (c) expanding the goals of ECMM beyond the European region; (d) implementing the ECMM Excellence Centre Initiative in Europe; and (e) the ECMM Global Guidelines and Neglected Orphan Disease Guidance Initiatives focusing on mucormycosis, rare mould diseases, rare yeast diseases, and endemic mycoses. We believe that these important initiatives and other strategies of the ECMM will advance the field of medical mycology and improve the outcome of patients with invasive mycoses worldwide.

show abstract

Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis

Cited by 12 publications

References 46 publications

Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo

Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo

Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together

Contact Info

Product

Resources

About